Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone386-462-2204
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.19 million
Profitability
Miscellaneous
Employees78
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Corp (NASDAQ:AGTC) released its quarterly earnings data on Thursday, February, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.41. The biotechnology company earned $5.93 million during the quarter. Applied Genetic Technologies had a negative net margin of 61.04% and a negative return on equity of 19.73%. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
What price target have analysts set for AGTC?
4 brokers have issued 1 year target prices for Applied Genetic Technologies' stock. Their predictions range from $5.00 to $15.00. On average, they anticipate Applied Genetic Technologies' share price to reach $7.75 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.
What is the consensus analysts' recommendation for Applied Genetic Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.
What are Wall Street analysts saying about Applied Genetic Technologies stock?
Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
- 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (4/10/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $5.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Currently the ACHM programs contribute 55% to our valuation, with the remaining 45% coming from XLRP. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (2/8/2019)
Has Applied Genetic Technologies been receiving favorable news coverage?
Media stories about AGTC stock have been trending positive on Friday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include Solid Biosciences (SLDB), Harpoon Therapeutics (HARP), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), LogicBio Therapeutics (LOGC), Sutro Biopharma (STRO), Novavax (NVAX), ADMA Biologics (ADMA), Eiger Biopharmaceuticals (EIGR), Gamida Cell (GMDA), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), Neon Therapeutics (NTGN), Compugen (CGEN) and AVITA MED LTD/S (AVMXY).
What other stocks do shareholders of Applied Genetic Technologies own?
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 58)
- Mr. William A. Sullivan, Chief Financial Officer (Age 48)
- Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 48)
- Dr. Nicholas Muzyczka, Co-Founder
- Dr. Barry J. Byrne, Co-Founder
Who are Applied Genetic Technologies' major shareholders?
Applied Genetic Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Steinberg Global Asset Management (0.97%). Company insiders that own Applied Genetic Technologies stock include Susan B Washer, William A Sullivan and William Aliski. View Institutional Ownership Trends for Applied Genetic Technologies.
Which major investors are buying Applied Genetic Technologies stock?
AGTC stock was purchased by a variety of institutional investors in the last quarter, including Steinberg Global Asset Management. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Susan B Washer, William A Sullivan and William Aliski. View Insider Buying and Selling for Applied Genetic Technologies.
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $4.55.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $82.67 million and generates $24.19 million in revenue each year. The biotechnology company earns $-21,300,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe.
What is Applied Genetic Technologies' official website?
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
